House members voice opposition to CMS reprints stance

Jonathan Blum
Jonathan Blum

Nearly two dozen members of Congress signaled solidarity with 41 medical boards and 33 physician associations in opposing the inclusion of textbooks and reprints in Sunshine Act reporting. The 23 House members—seven of them physicians—sent a letter to CMS to voice disagreement with an HHS decision to include textbooks and journals as “transfers of value” reportable under the Physician Payment Sunshine Act.  

“Ad agency and publisher representatives will continue to meet with government and industry leaders to pursue a quick resolution of the issues,” said John Kamp, executive director, Coalition for Healthcare Communication (CHC), which partnered with the American Medical Association in the effort.

“We've been disappointed so far,” Kamp told MM&M as this issue went to press, adding that advocates of the change were planning to meet with Jonathan Blum, CMS deputy administrator and director.

Failing that, said Kamp, they will attempt “a short line in one of the pieces of legislation expected to move [in 2014].”

The letter co-signers included seven Democrats and 16 Republicans. They stated, CMS's take that reprints and textbooks are not one of the exclusions from the reporting requirements “is inconsistent with the statutory language on its face, congressional intent, and the reality of clinical practice where patients benefit directly from improved physician medical knowledge.”

The decision also “presents a clear disincentive for clinicians to accept high-quality, independent educational materials,” they added in the letter.

You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.